Cardiomyopathy
MONDO:0004994A disease of the heart muscle or myocardium proper. Cardiomyopathies may be classified as either primary or secondary, on the basis of etiology, or on the pathophysiology of the lesion: hypertrophic, dilated, or restrictive.
Also known as: Cardiomyopathies, cardiomyopathy
819 clinical trials for this condition and its sub-types, 155 tagged with Cardiomyopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Cardiomyopathy
-
Intrinsic cardiomyopathy 16 trials · 695 incl. sub-types
6 sub-types
- Restrictive cardiomyopathy 18 trials · 329 incl. sub-types Sub-types →
- Hypertrophic cardiomyopathy 122 trials · 307 incl. sub-types Sub-types →
- Dilated cardiomyopathy 76 trials · 131 incl. sub-types Sub-types →
- Myocarditis 40 trials · 52 incl. sub-types Sub-types →
- Arrhythmogenic right ventricular cardiomyopathy 29 trials · 32 incl. sub-types Sub-types →
- Left ventricular noncompaction 3 trials · 4 incl. sub-types Sub-types →
-
Familial cardiomyopathy 2 trials · 217 incl. sub-types
9 sub-types
- Familial hypertrophic cardiomyopathy 2 trials · 85 incl. sub-types Sub-types →
- Familial restrictive cardiomyopathy 0 trials · 62 incl. sub-types Sub-types →
- Familial dilated cardiomyopathy 7 trials · 60 incl. sub-types Sub-types →
- Familial isolated arrhythmogenic right ventricular dysplasia 0 trials · 10 incl. sub-types Sub-types →
- PRKAG2-related cardiomyopathy 2 trials · 4 incl. sub-types Sub-types →
- Left ventricular noncompaction 3 trials · 4 incl. sub-types Sub-types →
- NKX2.5-related congenital, conduction and myopathic heart disease 0 trials
- Naxos disease 0 trials
- Fatal infantile encephalocardiomyopathy 0 trials Sub-types →
-
Tako-tsubo cardiomyopathy 16 trials
-
Cardiomyopathy due to anthracyclines 16 trials
-
Doxorubicin induced cardiomyopathy 7 trials
-
Chagas cardiomyopathy 3 trials
-
Extrinsic cardiomyopathy 3 trials
1 sub-type
- Alcoholic cardiomyopathy 0 trials
-
Non-compaction cardiomyopathy 3 trials
-
Idiopathic cardiomyopathy 2 trials · 3 incl. sub-types
2 sub-types
-
Keshan disease 0 trials
-
Uhl anomaly 0 trials
-
Autoimmune cardiomyopathy 0 trials
1 sub-type
- Autoimmune myocarditis 0 trials
Most studied deeper sub-types
-
Heart scan tracer may reveal Chemo's effect on amyloid buildup
Disease control Stopped earlyThis pilot study tests whether a special PET scan tracer called 18F florbetapir can detect changes in amyloid protein deposits in the heart of people with AL cardiac amyloidosis who are receiving chemotherapy. Four participants will have a PET/CT scan before starting chemotherapy…
Phase 4 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New cancer pill shows early promise, but trial halted
Disease control Stopped earlyThis early-stage trial tested an oral drug called TNO155, alone or with another drug (nazartinib), in 227 adults with advanced solid tumors like lung cancer, melanoma, and head/neck cancer. The main goal was to check safety and find the right dose. The study was terminated early,…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Heart drug trial halted early: MYK-224 studied for thick heart muscle
Disease control Stopped earlyThis study tested an experimental drug called MYK-224 in 18 adults with a type of heart disease that makes the heart muscle too thick and blocks blood flow. The goal was to see if the drug is safe and helps reduce symptoms. The trial was stopped early, so results are limited.
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Heart drug study halted early: what we know
Disease control Stopped earlyThis study tested an experimental drug called CRD-4730 in people with a rare inherited heart rhythm disorder (CPVT) that can cause dangerous fast heartbeats. Seven adults received two different doses of the drug and a placebo to check safety and how the body processes it. The stu…
Phase 2 • Sponsor: Cardurion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Experimental NK cell therapy for blood cancers hits early hurdle
Disease control Stopped earlyThis early-stage study tested a new drug called SAR445514, which helps the body's natural killer (NK) cells attack cancer cells in people with multiple myeloma or light-chain amyloidosis that had returned or stopped responding to other treatments. The study was terminated early, …
Phase 1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Which heart device lead lasts longest in kids? study aims to find out
Disease control Stopped earlyThis study looked at two types of implantable cardioverter defibrillator (ICD) leads in children and patients with congenital heart disease. The goal was to see which lead type lasts longer without breaking and is easier to remove if needed. The trial was terminated early, so res…
Sponsor: Charles Berul • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Experimental drug aims to stop rare heart disease in its tracks
Disease control Stopped earlyThis study tested a drug called inotersen in 31 people with a rare condition where a faulty protein builds up in the heart, causing damage. The drug is designed to lower levels of that protein. The trial was stopped early, so it's unclear if it works, but researchers hoped to see…
Phase 2 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New heart drug AZD0233 begins first safety tests in healthy volunteers
Disease control Stopped earlyThis early-stage trial tested the safety of a new drug called AZD0233 in 84 healthy adults aged 18 to 50. The drug is being developed for dilated cardiomyopathy, a condition where the heart becomes enlarged and weak. Participants received either the drug or a placebo, and researc…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Experimental gene therapy for rare muscle disease shows early promise but study halted
Disease control Stopped earlyThis study tested a gene therapy called SRP-9003 for people with limb-girdle muscular dystrophy type 2E (LGMD2E), a rare genetic disease that causes muscle weakness. The treatment aimed to deliver a working gene to muscle cells to help them produce a missing protein. Only 6 peopl…
Phase 1/2 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental heart slicing procedure tested on one patient
Disease control Stopped earlyThis early study tested a new procedure called SESAME that uses a wire threaded through blood vessels to slice away excess heart muscle in people with hypertrophic cardiomyopathy. Only one adult participated before the study was terminated. The goal was to see if the technique co…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Asthma drug safety check: dexpramipexole under Long-Term review
Disease control Stopped earlyThis study looked at the long-term safety of dexpramipexole in adults with severe eosinophilic asthma. Participants had already completed earlier phase 3 trials. The goal was to track side effects and asthma control over time. However, the study was terminated early, which may li…
Phase 3 • Sponsor: Areteia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Asthma drug trial halted midway: what it means for patients
Disease control Stopped earlyThis study tested a daily pill called dexpramipexole in 654 people with severe eosinophilic asthma, a type of asthma linked to high levels of certain white blood cells. The goal was to see if the drug could reduce severe asthma attacks over a year. However, the trial was terminat…
Phase 3 • Sponsor: Areteia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Experimental antibody trial for rare heart disease halted early
Disease control Stopped earlyThis phase 3 study tested an experimental drug called birtamimab in 208 people with advanced AL amyloidosis, a rare disease where abnormal proteins damage organs like the heart. Participants received either birtamimab or a placebo, plus standard chemotherapy. The goal was to see …
Phase 3 • Sponsor: Prothena Biosciences Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Asthma drug trial halted: Dexpramipexole's promise unfulfilled
Disease control Stopped earlyThis Phase 3 trial tested dexpramipexole, an oral drug, in over 1,000 people with severe eosinophilic asthma that was not well controlled by standard treatments. The goal was to see if it could reduce severe asthma attacks over a year. However, the study was terminated early, so …
Phase 3 • Sponsor: Areteia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Pompe disease drug trial halted after just 3 patients
Disease control Stopped earlyThis study tested an oral drug called duvoglustat in adults with Pompe disease, a rare genetic disorder that causes muscle weakness. Only 3 people took part, and the study was stopped early. Researchers looked at safety and whether the drug could improve walking distance and othe…
Phase 2 • Sponsor: Amicus Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 16:43 UTC
-
Experimental gene therapy tested for rare muscular dystrophy
Disease control Stopped earlyThis early-stage trial tested a gene therapy called SRP-9004 in just 4 people with limb girdle muscular dystrophy type 2D/R3, a rare muscle-weakening disease. The main goal was to check safety, not effectiveness. The study was terminated early, so results are limited.
Phase 1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:47 UTC
-
Promising drug combo for rare amyloidosis hits snag: trial ends early
Disease control Stopped earlyThis study tested a drug called ixazomib plus dexamethasone against other standard treatments for people with relapsed AL amyloidosis, a rare disease where abnormal proteins build up in organs. The trial aimed to see if the combination improved blood markers and slowed heart or k…
Phase 3 • Sponsor: Millennium Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:13 UTC
-
New PET tracer aims to reveal hidden immune activity in tumors and arteries
Diagnosis Stopped earlyThis Phase II study tested a radioactive tracer called 68GaNOTA-Anti-MMR-VHH2 to see if it can light up certain immune cells (macrophages) on PET scans. The trial included 29 people with head and neck cancer, lymphoma, atherosclerosis, or sarcoidosis. The goal was to see if the t…
Phase 2 • Sponsor: Universitair Ziekenhuis Brussel • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Can a PET scan spot silent heart danger from cancer drugs?
Diagnosis Stopped earlyThis pilot study tested whether a special PET scan (FDG-PET/CT) can detect hidden heart inflammation in cancer patients receiving immune checkpoint inhibitors (ICIs). The goal was to catch this inflammation early, before it becomes severe. Only 2 participants were enrolled, and t…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
Heart drug mavacamten tested in Non-Obstructive HCM trial
Symptom relief Stopped earlyThis Phase 3 study tested the drug mavacamten in 580 adults with symptomatic non-obstructive hypertrophic cardiomyopathy, a heart muscle condition that makes it harder for the heart to pump blood. Participants received either mavacamten or a placebo. The study measured changes in…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Heart pacemaker tweak aimed at easing chest pain and fatigue – but study stopped early
Symptom relief Stopped earlyThis study tested whether a personalized pacing algorithm (myPACE+) could improve quality of life and exercise capacity in people with non-obstructive hypertrophic cardiomyopathy who already have an implantable defibrillator. Only one person was enrolled before the trial was term…
Sponsor: Montefiore Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:04 UTC
-
Heart Disease's hidden toll: study tracks quality of life across mind, body, and spirit
Knowledge-focused Stopped earlyResearchers at the Cleveland Clinic are following 380 adults with hypertrophic cardiomyopathy, thoracic aortic dilatation, or radiation-induced heart disease. Participants complete a detailed survey at the start and again nine months later. The survey measures global, physical, e…
Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Scientists dive into cells to unravel costello Syndrome's secrets
Knowledge-focused Stopped earlyThis study collects small skin samples from children aged 2 to 17 with Costello syndrome or a related condition. Researchers will analyze the cells to understand how a mutation in the HRAS gene affects energy use and mitochondria. The goal is to learn more about the disease's und…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Mental health study aims to uncover Long-Term heart risks
Knowledge-focused Stopped earlyThis study followed 167 adults with mental health issues like anxiety, depression, or sleep problems who visited their primary care doctor. Researchers used health conversations and a blood test to track lifestyle changes and heart disease risks over up to 20 years. The goal was …
Sponsor: Region Skane • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
AI helps Non-Experts perform heart scans in rare heart condition
Knowledge-focused Stopped earlyThis study looked at whether healthcare workers without ultrasound training could use AI software to perform heart scans on people with hypertrophic obstructive cardiomyopathy (HOCM) who are eligible for the drug mavacamten. Participants had two scans on the same day: one by a no…
Sponsor: UltraSight • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Body clock may predict asthma attacks
Knowledge-focused Stopped earlyThis study looked at whether proteins that control our body's daily rhythms (clock proteins) can predict how severe asthma will get. Researchers monitored these proteins in the blood and sputum of 50 adults with severe eosinophilic asthma before and during treatment with mepolizu…
Sponsor: Medical University of Graz • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Hidden heart condition: study seeks to uncover missed diagnosis in heart failure patients
Knowledge-focused Stopped earlyThis study aims to find out how common transthyretin amyloidosis cardiomyopathy (ATTR-CM) is in Russian patients with a certain type of heart failure. Researchers will review medical records and then invite some patients for extra heart tests to confirm or rule out ATTR-CM. The g…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:47 UTC